Import Alert 66-80
The description below is from FDA’s GLP-1 concerns page, which names import alert 66-80. The alert document itself was not parsed into this page, so the green list of firms is not copied.
What the opened sources say
Section titled “What the opened sources say”- FDA says it established a green-list import alert (66-80) to help stop GLP-1 active pharmaceutical ingredients with potential quality concerns from entering the U.S. supply chain.
- FDA says the alert does not apply to GLP-1 API from manufacturers that, based on an FDA inspection or other FDA evaluation, appear to comply with FDA manufacturing standards.
- FDA says the action does not stop legal importation from compliant API manufacturers and does not create new limits on legal compounding of GLP-1 drugs.
Not stated here
Section titled “Not stated here”Product codes, firm names, and the alert’s revision history have to be read on the import-alert page. They are not reproduced here.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Regulatory status: U.S. FDA Import Alert 66-80, as described on FDA's unapproved GLP-1 drug page. Firm-level green list not copied.
Sources
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (primary, accessed 2026-11-20)
- Import Alert 66-80 (primary, accessed 2026-11-20)
Referenced by
A link from another wiki page is not evidence. Facts should point at the sources above.